Arabic Arabic English English French French German German
dark

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Applied Genetic Technologies Corporation today announced it had exceeded the enrollment target in the Company’s SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Nearly 48,000 boosters given yesterday; 14 community cases; 34 people in hospital; two in ICU

Next Post

Ketamine and psychological therapy helped severe alcoholics abstain for longer in trial

Related Posts
Total
0
Share